Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738397 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 673
- Enrollment target
NCT03738397 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 673 participants.
The verdict
NCT03738397, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 673 participants
- Enrollment target
Study Summary
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Interventions
- BIOLOGICAL Dupilumab
- BIOLOGICAL Upadacitinib
- DRUG Placebo to dupilumab
- DRUG Placebo to upadacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2020-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03738397
The ClinicalTrials.gov registry entry for NCT03738397 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 673 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dupilumab is the first listed.
NCT03738397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03738397 about?
NCT03738397 is a clinical study titled "A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis". This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
What is the current status of trial NCT03738397?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 673 participants. The study started on 2019-02-21. Estimated completion is 2020-12-09.
What interventions are being tested in trial NCT03738397?
The interventions under investigation include: Dupilumab (BIOLOGICAL), Upadacitinib (BIOLOGICAL), Placebo to dupilumab (DRUG), Placebo to upadacitinib (DRUG).
Who is sponsoring clinical trial NCT03738397?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.